Rein Therapeutics (DE:015A)
BERLIN:015A
015A Stock Chart & Stats
€3.14
€0.00(0.00%)
At close: 4:00 PM EST
€3.14
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.14 - €3.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€70.72M
Enterprise Value€31.51M
Total Cash (Recent Filing)€4.45M
Total Debt (Recent Filing)€4.92M
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding85,539,030
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.90Price Target Upside119.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Funding RunwayThe $50M offering and management's expectation that proceeds plus existing cash fund operations into 2028 materially reduces near-term liquidity risk. This allows uninterrupted execution of the Phase 2 LTI-03 program and gives time to reach clinical milestones without immediate financing pressure.
Modest LeverageLow absolute debt (TTM total debt $4.9M vs equity $11.6M) limits interest burden and reduces bankruptcy risk relative to highly leveraged peers. For a cash‑burn biotech, modest leverage preserves strategic flexibility to prioritize R&D spending or time external financing more selectively.
Focused Clinical PipelineA concentrated clinical-stage program centered on LTI-03 in idiopathic pulmonary fibrosis provides clear, durable value inflection points. Successful Phase 2 results would materially change the company’s prospects and create opportunities for partnerships or further development funding.
Bears Say
No Revenue, Large LossesRein reports no revenue and a TTM net loss of $50.2M, indicating the company has no commercialized products and relies on capital markets. Persistent sizable losses erode equity, increase dependence on financing, and make long-term sustainability contingent on clinical success rather than operational cash flow.
Negative Cash GenerationOperating and free cash flow are both -$16.6M TTM, showing ongoing cash burn despite some improvement. Continued negative cash generation requires periodic external funding, constrains R&D agility, and raises execution risk if capital markets tighten or milestones slip.
Equity Erosion & Dilution RiskEquity has fallen sharply year-over-year, reflecting sustained losses and capital changes. A reduced equity buffer increases the likelihood and magnitude of future dilutive financings to sustain trials, amplifying shareholder dilution risk and limiting retained capital resilience.
Rein Therapeutics News
015A FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was €3.14 and its highest was €3.30 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is €70.72M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 85,539,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in DE:015A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.90 (119.68% Upside)
€6.90 (119.68% Upside)
Insider Transactions
Bought Shares
Worth €64.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.85%
12-Months-Change
Fundamentals
Return on Equity
-258.45%
Trailing 12-Months
Asset Growth
-54.38%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
015A Stock 12 Month Forecast
Average Price Target
€6.90
▲(119.68% Upside)
Technical Analysis
Options Prices
Currently, No data available
---